Drug Trial Radar · NCT04571437
Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)
Last checked: Nov 19, 2026Latest source record: Oct 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
204
Planned (sponsor's estimate)
Start
Mar 1, 2020
Primary completion
Oct 31, 2021
Study completion Apr 30, 2022
Sponsor
- Lead sponsor
- Cairo UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase II clinical trial designed to test the effect of combining endocrinal therapy (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of female breast cancer with ER positive disease.
Conditions
- Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- Metastatic Breast Cancer
Interventions
CapecitabineDrug
Capecitabine metronomic combined with Letrozole
Letrozole 2.5mgDrug
Letrozole daily alone
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6 months Progression free survival rateTime frame: 6 months from the start of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Faculty of Medicine, Cairo University
Cairo, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.